Literature DB >> 30225281

Identification of potential biomarkers of head and neck squamous cell carcinoma using iTRAQ based quantitative proteomic approach.

Niraj Babu1,2, Sonali Mohan1, Vishalakshi Nanjappa1, Sandip Chavan1, Jayshree Advani1,2, Aafaque Ahmed Khan1,3, Santosh Renuse1, Aneesha Radhakrishnan1, T S Keshava Prasad1, Rekha V Kumar4, Jay Gopal Ray5, Manjusha Biswas6, Saravanan Thiyagarajan7, Joseph A Califano8,9, David Sidransky8, Harsha Gowda1,2, Aditi Chatterjee1.   

Abstract

Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in India. Despite improvements in treatment strategy, the survival rates of HNSCC patients remain poor. Thus, it is necessary to identify biomarkers that can be used for early detection of disease. In this study, we employed iTRAQ-based quantitative mass spectrometry analysis to identify dysregulated proteins from a panel of head and neck squamous cell carcinoma (HNSCC) cell lines. We identified 2468 proteins, of which 496 proteins were found to be dysregulated in at least two out of three HNSCC cell lines compared to immortalized normal oral keratinocytes. We detected increased expression of replication protein A1 (RPA1) and heat shock protein family H (Hsp110) member 1 (HSPH1), in HNSCC cell lines compared to control. The differentially expressed proteins were further validated using parallel reaction monitoring (PRM) and western blot analysis in HNSCC cell lines. Immunohistochemistry-based validation using HNSCC tissue microarrays revealed overexpression of RPA1 and HSPH1 in 15.7% and 32.2% of the tested cases, respectively. Our study illustrates quantitative proteomics as a robust approach for identification of potential HNSCC biomarkers. The proteomic data has been submitted to ProteomeXchange Consortium (http://www.proteomecentral.proteomexchange.org) via the PRIDE public data repository accessible using the data identifier - PXD009241.

Entities:  

Keywords:  HNSCC; Mass spectrometry; OKF6/TERT1; Parallel reaction monitoring; iTRAQ

Year:  2018        PMID: 30225281      PMCID: PMC6139602          DOI: 10.1016/j.dib.2018.05.100

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data This data set provides insights into proteomic alterations in HNSCC cell lines compared to normal oral keratinocyte cell line and validates candidate biomarkers using targeted proteomics approach using PRM and IHC. The data provides a useful resource to study proteins altered in HNSCC and will aid in identification of early detection biomarkers.

Data

The data represents iTRAQ-based quantitative proteomic analysis of HNSCC cell lines - CAL 27, FaDu and JHU-O28, compared to immortalized normal oral keratinocytes - OKF6/TERT1. A representative work flow of the study is depicted in Supplementary Fig. 1A. The study led to the identification of 2468 proteins, among which 496 proteins were dysregulated (fold change ≥ 2) in at least two out of three HNSCC cell lines. The complete list of proteins and peptides identified in this study is provided in Supplementary Table 1. Overexpression of RPA1 and HSPH1 identified in HNSCC cell lines in comparison to OKF6/TERT1 was validated using PRM and western blot. Further, the relative abundance of RPA1 and HSPH1 were assessed in HNSCC primary tissue compared to normal head and neck tissue samples using IHC.

Experimental design

Cell culture

FaDu and CAL 27 cell lines were purchased from ATCC (Manassas, VA). Immortalized, non-transformed normal oral keratinocytes OKF6/TERT1 was a kind gift from Dr. James Rheinwald at Brigham and Women׳s Hospital in Boston, MA [1]. As described earlier, FaDu and JHU-O28 were cultured in RPMI-1640 culture media supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin solution [2]. CAL 27 and OKF6/TERT1 were cultured in keratinocyte serum-free media (KSFM) (Life Technologies, Grand Island, NY) supplemented with bovine pituitary extract (25 mg/ml), calcium chloride (0.4 mM), epidermal growth factor (0.2 ng/ml) and 1% penicillin/streptomycin solution. All the cell lines were grown and maintained at 37 °C in a humidified incubator with 5% CO2.

Sample preparation for LC–MS/MS analysis

Sample preparation for mass spectrometry analysis was performed as described previously [3]. Each cell line was grown to 70% confluency. The cells were then maintained in serum-free growth media for 12 h prior to harvesting for protein extraction. Cells were lysed using lysis buffer (2% SDS, 5 mM sodium fluoride, 1 mM β-glycerophosphate and 1 mM sodium orthovanadate in 50 mM triethyl ammonium bicarbonate (TEABC)). Protein concentration was determined using bicinchoninic acid (BCA) assay (Pierce, Waltham, MA) [4]. Filter-assisted sample preparation (FASP) was used to reduce SDS concentration in the sample as described earlier [5]. Briefly, equal amounts of protein from each cell line was reduced using tris(2-carboxyethyl)phosphine (TCEP) at 60 °C for 1 h and alkylated using methyl methanethiosulfonate (MMTS) for 20 min at room temperature. The samples were then digested using trypsin (Promega, San Luis Obispo, CA) overnight at 37 °C.

iTRAQ labeling and SCX fractionation

Peptides from each cell line were labelled using iTRAQ 8-plex kit (AB SCIEX, Washington, D.C.) in two technical replicates as per manufacturer׳s instructions. OKF6/TERT1 was labelled using iTRAQ label 113 and 114, CAL 27 with 115 and 116, FaDu with 117 and 118, and JHU-O28 with 119 and 121. The iTRAQ-labeled samples were pooled, dried and subjected to SCX fractionation, as described earlier [6]. Briefly, the samples were reconstituted in 25% acetonitrile and, adjusted to pH 2.8 using orthophosphoric acid. Sample fractionation was carried out on polysulfoethyl A column (200 × 4.6 mm, 5 μm, 200Å, PolyLC Inc., Columbia, MD) on Agilent 1260 HPLC platform. Peptide fractionation was carried out using a linear gradient of 0–60% of solvent B (10 mM KH2PO4, 350 mM KCl, 25% acetonitrile) over a period of 50 min at a constant flow rate of 350 μl/min. The samples were concatenated and pooled into 25 fractions, reconstituted in 0.1% formic acid and desalted using C18 Stage Tips (3 M Empore, St. Paul, MN).

LC–MS/MS

iTRAQ based LC–MS/MS analysis was carried out using LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific, Bremen, Germany) interfaced with Easy-nLC II system (Thermo Scientific, Bremen, Germany). Samples were loaded on a trap column (75 μm × 2 cm, Magic C18Aq, 5 μm, 100Å) and washed using Solvent A (0.1% formic acid) at a flow rate of 3 μl/min. Samples were then resolved on an analytical column (75 μm × 12 cm, Magic C18 Aq, 3 μm, 100Å) at 350 nl/min flow rate using a linear gradient of 7–30% of Solvent B (0.1% formic acid in 95% acetonitrile) over 75 min. MS and MS/MS scans were at a mass resolution of 60,000 at 400 m/z and 15,000 at 400 m/z, respectively. Full MS scans were acquired in m/z range of 350–1800 m/z. For each cycle, twenty most abundant precursor ions with charge state ≥ 2 were sequentially isolated. Higher energy collision dissociation was used as the activation method with 40% normalized collision energy. Isolation width used was 2 m/z. Precursor ions with single charge or unassigned charges were rejected.

Data analysis

Proteome Discoverer (Version 1.4) software suite (Thermo Scientific, Bremen, Germany) was used for protein identification and quantification. Mass spectrometry data was queried against NCBI Human RefSeq protein database (Version 81) using Sequest and Mascot (version 2.4) search algorithms. Oxidation of methionine was set to dynamic modification in the search parameters while static modifications included - carbamidomethylation at cysteine and iTRAQ 8-plex modification at N-terminus of the peptide and lysine. Trypsin was specified as protease with one missed cleavage allowed. The precursor mass tolerance was set to 10 ppm and fragment mass tolerance was set to 0.1 Da. Decoy database searches were carried out to calculate the false discovery rate (FDR). 1% FDR cut-off at PSM, peptide and protein levels were considered for protein identification. The protein abundance ratios in HNSCC cell lines was obtained as follows: CAL 27 (115+116)/OKF6/TERT1 (113+114), FaDu (117+118)/OKF6/TERT1 (113+114) and JHU-O28 (119+121)/OKF6/TERT1 (113+114). The representative spectra of two proteins, RPA1 and HSPH1 is provided in Supplementary Fig. 1B.

Parallel reaction monitoring (PRM)

Select proteins identified from the mass spectrometry-based proteomic analysis were validated using PRM on a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). The full scan event was carried out between 120.0 and 1240.0 mass selection with ion injection time of 120 ms and a resolution of 17,500. The PRM scans were carried out in MS2 mode with 1 microscan set to a resolution of 17,500. The target AGC was set to 2 × 105 with an isolation window of 0.7 m/z. The data was acquired using an isolation offset of 0.2 m/z with a first fixed mass of 120.0 m/z. The normalized collision energy was set to 27%. The data was acquired in triplicate and analysed on Skyline software (version 3.5) [7] (Fig. 1A, Table 1). Statistical significance (p-value) for the fold changes was calculated using two-sample t-test.
Fig. 1

A. Bar graph depicting the relative abundance of RPA1 and HSPH1 in HNSCC cell lines (JHU-O28, FaDu and CAL27) and normal oral keratinocytes OKF6/TERT1 using parallel reaction monitoring (p-value ≤ 0.05). B. Western blot analysis to identify the relative expression of RPA1 and HSPH1 in HNSCC cell lines (JHU-O28, FaDu and CAL27), compared to normal oral keratinocyte (OKF6/TERT1). C. Representative sections from HNSCC tissues and normal head and neck tissue probed with anti-RPA1 and anti-HSPH1 antibodies.

Table 1

List of peptides of RPA1 and HSPH1 used to study the relative abundance in HNSCC cell lines using parallel reaction monitoring.

Protein namePeptide sequenceChargem/zFold changep-valueFold changep-valueFold changep-value
(O28/OKF6/TERT1)(FaDu/OKF6/TERT1)(CAL 27/OKF6/TERT1)
RPA1LFSLELVDESGEIR3536.20.20.3150.25.3E−0748.73.7E−05
HSPH1AGGIETIANEFSDR2740.31.40.1248.04.7E−0452.42.5E−04
A. Bar graph depicting the relative abundance of RPA1 and HSPH1 in HNSCC cell lines (JHU-O28, FaDu and CAL27) and normal oral keratinocytes OKF6/TERT1 using parallel reaction monitoring (p-value ≤ 0.05). B. Western blot analysis to identify the relative expression of RPA1 and HSPH1 in HNSCC cell lines (JHU-O28, FaDu and CAL27), compared to normal oral keratinocyte (OKF6/TERT1). C. Representative sections from HNSCC tissues and normal head and neck tissue probed with anti-RPA1 and anti-HSPH1 antibodies. List of peptides of RPA1 and HSPH1 used to study the relative abundance in HNSCC cell lines using parallel reaction monitoring.

Western blot

Western blot was carried out as described previously [8] to study the expression of proteins - RPA1 and HSPH1, across HNSCC cell lines (CAL 27, FaDu and JHU-O28) compared to human normal oral keratinocyte (OKF6/TERT1) (Fig. 1B). Cell lines were cultured to 70% confluence and harvested in modified RIPA buffer containing 50 mM TrisHCl, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 2 mM EDTA, and 50 mM NaF, supplemented with protease inhibitor (Roche, Indianapolis, IN) and phosphatase inhibitor cocktail (Thermo Scientific, Bremen, Germany). Protein concentration was determined using BCA assay (Pierce, Waltham, MA) and 30 μg equivalent protein from each cell lysate was resolved on SDS-PAGE. Subsequently, the resolved proteins were transferred on a nitrocellulose membrane and probed using mouse monoclonal anti-RPA1 antibody (Cat # sc-48425; Santa Cruz Biotechnology, Dallas, TX) and rabbit polyclonal anti-HSPH1 antibody (Cat # HPA028675; Sigma, Darmstadt, Germany).

Immunohistochemistry (IHC)

Immunohistochemistry on commercially procured tissue microarrays (TMA) was performed as described previously [3]. Commercially available HNSCC TMAs were purchased from US Biomax (Cat # HN242a and HN483; US Biomax Inc., Derwood, MD). Briefly, the formalin fixed paraffin embedded tissue sections were deparaffinised, followed by antigen retrieval using citrate buffer (0.01 M Trisodium citrate buffer, pH 6) for 20 min. To inhibit the activity of endogenous peroxidases, the sections were quenched with blocking solution (methanol: water mixed in the ratio of 3:1) for 20 min. The sections were then washed using phosphate buffered saline and treated with 5% goat serum to block non-specific binding of antibodies. The sections were incubated in mouse monoclonal anti-RPA1 antibody (Cat # sc-48425; Santa Cruz Biotechnology) and polyclonal rabbit anti-HSPH1 antibody (Cat # HPA028675; Sigma) overnight at 4 °C. Following this, the sections were treated with secondary antibody conjugated with horseradish peroxidase (Bangalore Genei, India) before the addition of DAB chromogen (Dako, Glostrup, Denmark). Once the colored substrate was formed, the reaction was quenched using water and counterstained using hematoxylin solution. The tissue sections were examined under the microscope by two expert pathologists independently and scored based on the expression of proteins in the tissue sections. The tissue expression of RPA1 and HSPH1 were scored on a scale of 0–3, with 0 representing absence of staining, + 1 representing weak staining, + 2 representing moderate staining, and + 3 representing intense staining (Fig. 1C; Table 2A, Table 2B). Two-tailed Chi-square test was carried out to evaluate the p-value significance of RPA1 and HSPH1 expression in HNSCC.
Table 2A

Summary of immunohistochemical validation of RPA1 in HNSCC and normal tissues.

Staining intensityNormalHNSCC
0–1+(Negative–Weak)1148
2+–3+(Moderate–Strong)19
p-value5.04E−01
Subcellular location of stainingPredominantly cytoplasmic
Table 2B

Summary of immunohistochemical validation of HSPH1 in HNSCC and normal tissues.

Staining intensityNormalHNSCC
0–1+(Negative–Weak)1140
2+–3+(Moderate–Strong)119
p-value9.3E−02
Subcellular location of stainingPredominantly cytoplasmic
Summary of immunohistochemical validation of RPA1 in HNSCC and normal tissues. Summary of immunohistochemical validation of HSPH1 in HNSCC and normal tissues.
Subject areaBiology
More specific subject areaCancer proteomics
Type of dataMass spectrometry raw files, tables, figures
How data was acquiredLTQ Orbitrap Velos mass spectrometer (Thermo Scientific, Bremen, Germany)
Proteome Discoverer (Version 1.4) software suite (Thermo Scientific, Bremen, Germany)
SEQUEST and Mascot search engines
NCBI Human RefSeq protein database (Version 81)
Data formatAnalysed output data
Experimental factorsQuantitative proteomic analysis of head and neck squamous cell carcinoma (HNSCC) cell lines
Experimental featuresiTRAQ-based quantitative proteomic analysis of HNSCC cell lines, CAL 27, FaDu and JHU-O28 compared to immortalized normal oral keratinocytes, OKF6/TERT1. Validation of candidate proteins using parallel reaction monitoring (PRM), western blotting and immunohistochemistry (IHC)
Data source locationBangalore, India
Data accessibilityData is available here and via a web application (ProteomeXchange Consortium - http://www.proteomecentral.proteomexchange.org) via the PRIDE public data repository accessible using the data identifier - PXD009241
  8 in total

1.  Skyline: an open source document editor for creating and analyzing targeted proteomics experiments.

Authors:  Brendan MacLean; Daniela M Tomazela; Nicholas Shulman; Matthew Chambers; Gregory L Finney; Barbara Frewen; Randall Kern; David L Tabb; Daniel C Liebler; Michael J MacCoss
Journal:  Bioinformatics       Date:  2010-02-09       Impact factor: 6.937

2.  Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics.

Authors:  M A Dickson; W C Hahn; Y Ino; V Ronfard; J Y Wu; R A Weinberg; D N Louis; F P Li; J G Rheinwald
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

3.  Dysregulation of splicing proteins in head and neck squamous cell carcinoma.

Authors:  Aneesha Radhakrishnan; Vishalakshi Nanjappa; Remya Raja; Gajanan Sathe; Sandip Chavan; Raja Sekhar Nirujogi; Arun H Patil; Hitendra Solanki; Santosh Renuse; Nandini A Sahasrabuddhe; Premendu P Mathur; T S Keshava Prasad; Prashant Kumar; Joseph A Califano; David Sidransky; Akhilesh Pandey; Harsha Gowda; Aditi Chatterjee
Journal:  Cancer Biol Ther       Date:  2016-02-06       Impact factor: 4.742

4.  Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.

Authors:  Nazia Syed; Sandip Chavan; Nandini A Sahasrabuddhe; Santosh Renuse; Gajanan Sathe; Vishalakshi Nanjappa; Aneesha Radhakrishnan; Remya Raja; Sneha M Pinto; Anand Srinivasan; T S Keshava Prasad; Kotteazeth Srikumar; Harsha Gowda; Vani Santosh; David Sidransky; Joseph A Califano; Akhilesh Pandey; Aditi Chatterjee
Journal:  Proteomics       Date:  2015-01       Impact factor: 3.984

5.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

6.  A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.

Authors:  Aneesha Radhakrishnan; Vishalakshi Nanjappa; Remya Raja; Gajanan Sathe; Vinuth N Puttamallesh; Ankit P Jain; Sneha M Pinto; Sai A Balaji; Sandip Chavan; Nandini A Sahasrabuddhe; Premendu P Mathur; Mahesh M Kumar; T S Keshava Prasad; Vani Santosh; Geethanjali Sukumar; Joseph A Califano; Annapoorni Rangarajan; David Sidransky; Akhilesh Pandey; Harsha Gowda; Aditi Chatterjee
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

7.  A draft map of the human proteome.

Authors:  Min-Sik Kim; Sneha M Pinto; Derese Getnet; Raja Sekhar Nirujogi; Srikanth S Manda; Raghothama Chaerkady; Anil K Madugundu; Dhanashree S Kelkar; Ruth Isserlin; Shobhit Jain; Joji K Thomas; Babylakshmi Muthusamy; Pamela Leal-Rojas; Praveen Kumar; Nandini A Sahasrabuddhe; Lavanya Balakrishnan; Jayshree Advani; Bijesh George; Santosh Renuse; Lakshmi Dhevi N Selvan; Arun H Patil; Vishalakshi Nanjappa; Aneesha Radhakrishnan; Samarjeet Prasad; Tejaswini Subbannayya; Rajesh Raju; Manish Kumar; Sreelakshmi K Sreenivasamurthy; Arivusudar Marimuthu; Gajanan J Sathe; Sandip Chavan; Keshava K Datta; Yashwanth Subbannayya; Apeksha Sahu; Soujanya D Yelamanchi; Savita Jayaram; Pavithra Rajagopalan; Jyoti Sharma; Krishna R Murthy; Nazia Syed; Renu Goel; Aafaque A Khan; Sartaj Ahmad; Gourav Dey; Keshav Mudgal; Aditi Chatterjee; Tai-Chung Huang; Jun Zhong; Xinyan Wu; Patrick G Shaw; Donald Freed; Muhammad S Zahari; Kanchan K Mukherjee; Subramanian Shankar; Anita Mahadevan; Henry Lam; Christopher J Mitchell; Susarla Krishna Shankar; Parthasarathy Satishchandra; John T Schroeder; Ravi Sirdeshmukh; Anirban Maitra; Steven D Leach; Charles G Drake; Marc K Halushka; T S Keshava Prasad; Ralph H Hruban; Candace L Kerr; Gary D Bader; Christine A Iacobuzio-Donahue; Harsha Gowda; Akhilesh Pandey
Journal:  Nature       Date:  2014-05-29       Impact factor: 49.962

8.  Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer.

Authors:  Tejaswini Subbannayya; Pamela Leal-Rojas; Mustafa A Barbhuiya; Remya Raja; Santosh Renuse; Gajanan Sathe; Sneha M Pinto; Nazia Syed; Vishalakshi Nanjappa; Arun H Patil; Patricia Garcia; Nandini A Sahasrabuddhe; Bipin Nair; Rafael Guerrero-Preston; Sanjay Navani; Pramod K Tiwari; Vani Santosh; David Sidransky; T S Keshava Prasad; Harsha Gowda; Juan Carlos Roa; Akhilesh Pandey; Aditi Chatterjee
Journal:  BMC Cancer       Date:  2015-11-04       Impact factor: 4.430

  8 in total
  1 in total

1.  Quantitative proteomics identifies a plasma multi-protein model for detection of hepatocellular carcinoma.

Authors:  Zhenhua Du; Xinyi Liu; Xiaojun Wei; Hongbo Luo; Peiyao Li; Mengting Shi; Bingqian Guo; Ying Cui; Zhenglin Su; Jifeng Zeng; Anfeng Si; Pengbo Cao; Gangqiao Zhou
Journal:  Sci Rep       Date:  2020-09-23       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.